课题基金 / 基金详情

Improving the Canadian drug approval framework: Evaluation of effectiveness; safety and economic uncertainty associated with new cancer medicines using real world evidence

Improving the Canadian drug approval framework: Evaluation of effectiveness; safety and economic uncertainty associated with new cancer medicines using real world evidence
改进加拿大药品审批框架：有效性评估；
批准号：
407517
负责人：
Timilshina NARHARI
金额：
$2.55万
依托单位：
Ontario Health - CCO - Cancer Care Ontario (Toronto)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-04-01 至 2020-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=407517&lang=en
关键词：
Drug Approval Framework Economic Evaluation Effectiveness Efficacy Real World Evidence

项目摘要

项目成果

Timilshina NARHARI的其他基金

相似基金

相关文献

中文摘要
翻译
随机临床试验（rct）是必要的，以证明药物在理想的患者和环境中起作用，并获得新药许可。然而，并不是所有的问题都可以通过随机试验来回答，因为患者是在现实世界中接受治疗的
英文摘要
Randomized clinical trials (RCTs) are necessary to show that a drug works in ideal patients and circumstances, and to obtain a licence for new drugs. However, not all questions can be answered by randomized trials because patients treated in the real worl
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PSA velocity in men starting 5-alpha-reductase inhibitors at the time of starting active surveillance is a predictor of pathological progression in low-risk prostate cancer
Initiation of Bhutan Cancer Registry: experiences, progress and future challenges from low-middle income country
  • 批准号：
    311309
  • 项目类别：
  • 资助金额：
    $0.11万
  • 财政年份：
    2014
  • 负责人：
    Timilshina NARHARI
  • 依托单位：
    University of Toronto
海外基金